“Safety of Incretin-Based Therapies Hotly Debated”. The headline from WebMD drew my attention. Incretins were part of the treatment that caused more death in the more aggressively “drug-managed” type 2 diabetics. The article begins by stating that researchers express concern about the safety of “incretins” – a class of drugs that raise insulin to lower blood glucose. They do indeed lower glucose but raise the risk of so many diseases that the wisdom of the drug’s use is in question. Your goal, when you follow your Blood Code, is the opposite, it is to lower insulin and improve your insulin sensitivity.
So where is the debate? The article continues, ONE researcher, Dr. Michael A, Nauck, “begs to differ.” One M.D. against years of clinical data makes a debate? I looked up Dr. Nauck’s conflict of interest statement, published on an article from 2012 on WebMD. Is it possible for someone to have millions of dollars of pharmaceutical interest at stake and legitimately provide a debate that impacts your life and medical treatment? Decide for yourself, these are his active conflicts of interest.
Type 2 diabetes is reversible with properly advised dietary and fitness intervention. The scientific community must not put a sugar-coating on a class of drugs that comes with significant if not excessive risk. Conflict of interest aside, the medical industry is here to serve the greater good of the public, right? Right?
Faculty and Disclosures: http://www.medscape.org/viewarticle/772418
Michael A. Nauck, MD, PhDServed as an advisor or consultant for: Amylin Pharmaceuticals, Inc.; AstraZeneca Pharmaceuticals LP; Berlin-Chemie AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Diartis Pharmaceuticals; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; GlaxoSmithKline; Intarcia Therapeutics, Inc.; MannKind Corporation; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation; Novo Nordisk; sanofi-aventis; Takeda Pharmaceuticals North America, Inc.; Versartis, Inc.; Wyeth Pharmaceuticals Inc.
Served as a speaker or a member of a speakers bureau for: Amylin Pharmaceuticals, Inc.; AstraZeneca Pharmaceuticals LP; Berlin-Chemie AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Diartis Pharmaceuticals; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; GlaxoSmithKline; Intarcia Therapeutics, Inc.; MannKind Corporation; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation; Novo Nordisk; sanofi-aventis; Takeda Pharmaceuticals North America, Inc.; Versartis, Inc.; Wyeth Pharmaceuticals Inc.
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Berlin-Chemie AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; GlaxoSmithKline; Merck Sharp & Dohme Corp.; MetaCure Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Roche; Tolerx, Inc.


